Background Exacerbations are major causes of morbidity in individuals with chronic respiratory diseases such as chronic ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD ...

Previous research has prompted warnings from North American and European health agencies of severe exacerbations associated with gabapentinoid use by patients with COPD. The researchers compared data ...

Chronic obstructive pulmonary disease (COPD) is a group of diseases that affect the lungs. The disease makes it difficult to breath and progressively gets worse. About 15 million Americans have been ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has highlighted recent advances in understanding and managing COPD, particularly in relation to its ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...